Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
AMAZE 8: zenagamtide versus semaglutide in adults with overweight or obesity and type 2 diabetes mellitus
2024-520446-31-00Phase 3Authorised
- Sponsor
- Novo Nordisk
- Start
- May 2026
- Modality
- Recombinant Proteins and Enzymes, Peptides, Small Molecules
- Countries
- 14
01
Overview
Phase 3, randomised, double-blind trial in obesity, Overweight and type 2 diabetes mellitus (T2DM) comparing Zenagamtide once weekly with Wegovy once weekly (2 arms). Primary endpoint: Relative change in body weight. Planned start May 2026; status: authorised.
02
Drugs
amycretinsemaglutide
03
Conditions
obesityOverweighttype 2 diabetes mellitus (T2DM)
Beyond the preview
Go deeper on 2024-520446-31-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2024-520446-31-00.